NCT05406362: An ongoing trial by Vaderis Therapeutics AG
This trial is ongoing. It must report results 3 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05406362 |
|---|---|
| Title | A Randomised, Placebo Controlled, Double Blind, Multicentre Proof of Concept Study to Assess the Safety and Efficacy of Two Doses of VAD044 in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 18, 2022 |
| Completion date | March 31, 2025 |
| Required reporting date | March 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |